Section Arrow
BGNE.NASDAQ
- BeiGene Ltd
Quotes are at least 15-min delayed:2024/05/16 09:28 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
164.88 
1-M High
169.38 
Volume 
-- 
Bid
166.67
Ask
169
Day Low
-- 
Open
-- 
1-M Low
126.9681 
Market Cap 
17.24B 
Currency USD 
P/E -- 
%Yield
10-SMA 162.93 
20-SMA 153.7 
50-SMA 154.97 
52-W High 245.74 
52-W Low 126.9681 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.54/-0.65
Enterprise Value
17.46B
Balance Sheet
Book Value Per Share
32.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.46B
Operating Revenue Per Share
17.32
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%-- 
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%7.98PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed:2024/05/16 09:28 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, theUnited States, and the Rest of the world.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.